Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hypercitrullination is the excessive citrullination of multiple intracellular proteins, primarily in immune cells, driven by overactivation of peptidylarginine deiminase (PAD) enzymes. This process is often triggered by a rapid influx of calcium ions into the cell cytoplasm, frequently due to membranolytic pathways like the perforin-granzyme pathway or complement activation. Hypercitrullination is implicated in the pathogenesis of rheumatoid arthritis, where it generates neoantigens that drive autoimmunity through the production of anti-citrullinated protein antibodies (ACPAs).
N/A (Hypercitrullination is a process, not a drug target with a defined mechanism of action.)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypercitrullination.